毛细血管扩张定量作为系统性硬化血管病变进展标志物的临床价值
本研究基于国际系统性硬化症相关血管病变横断面研究进行回顾性分析,探讨毛细血管扩张的部位和数量与疾病特征的关系,以及患者与医生报告数量的一致性。结果显示面部和手部毛细血管扩张数量较高与钙质沉着、指端溃疡和肺动脉高压患病率较高相关,多因素分析中肺动脉高压、指端溃疡和钙质沉着与面部毛细血管扩张较高相关。患者与医生报告的数量一致性在面部和前臂为中等,手部相对较弱。
要点
- 面部和手部毛细血管扩张数量较高与钙质沉着、指端溃疡和肺动脉高压患病率较高相关。
- 多因素分析中肺动脉高压、指端溃疡和钙质沉着与面部毛细血管扩张较高相关。
- 患者与医生报告的毛细血管扩张数量一致性在面部和前臂为中等,手部相对较弱。
核心结论
- 毛细血管扩张数量可考虑作为系统性硬化症血管并发症(包括肺动脉高压、指端溃疡和钙质沉着)的补充生物标志物。
研究设计与样本
- 对一项大型、横断面国际系统性硬化症相关血管病变研究进行回顾性分析,纳入临床医生和患者对毛细血管扩张数量的评估。
主要发现
- 单因素分析中,面部和手部毛细血管扩张数量较高与钙质沉着、指端溃疡和肺动脉高压患病率较高相关(P < 0.001-0.003)。
- 多因素分析中,肺动脉高压、指端溃疡和钙质沉着的存在与面部毛细血管扩张较高相关(P < 0.05)。
- 包含毛细血管扩张数量和部位的逻辑回归模型提高了肺动脉高压检测的准确性(精确召回曲线下面积0.824-0.875)。
- 临床医生与患者报告的毛细血管扩张数量一致性在面部和前臂为中等(kappa分别为0.648和0.605,P < 0.001),手部相对较弱(kappa 0.584,P < 0.001)。
关键数值与推荐
- 毛细血管扩张计数分类为0、1-6、7-15或>15,评估部位包括面部、前臂和手部。
- 使用比例优势逻辑回归检查各部位毛细血管扩张计数与人口统计学和临床特征的关系,使用二元逻辑回归模型检查毛细血管扩张计数对识别共存肺动脉高压的准确性。
临床怎么用
- 毛细血管扩张数量可作为系统性硬化症血管并发症的补充生物标志物,但患者报告的数量需要进一步优化解剖区域和指导水平以提高可靠性和可行性。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Telangiectasia are common in SSc. We explored the relationship between the site and quantity of telangiectasia with disease characteristics in SSc, and the agreement between patient- and physician-reported quantification of telangiectasia. METHODS: A retrospective analysis of a large, cross-sectional international SSc-related vasculopathy study was undertaken, including clinician and patient assessments of telangiectasia counts (0, 1-6, 7-15 or >15) in the face, forearms and hands. Relationships between telangiectasia count at each site, demographics and clinical features including calcinosis, digital ulceration (DU) and pulmonary arterial hypertension (PAH) were examined using proportional odds logistic regression. A binary logistic regression model examined the value of telangiectasia counts on the accuracy of identifying co-existent PAH. Concordance between clinician- and patient-reported telangiectasia counts at each anatomical site was tested. RESULTS: Higher telangiectasia counts over the face and hands were associated with higher prevalence of calcinosis, DU and PAH in univariate analysis (P < 0.001-0.003). In multivariate analysis, the presence of PAH, DU and calcinosis were associated with higher facial telangiectasia (P < 0.05). The logistic regression model for the detection of PAH was enhanced with inclusion of telangiectasia count and site (area under the precision recall curve 0.824-0.875). Strength of agreement between clinician- and patient-reported telangiectasia counts were moderate for face and forearms (kappa 0.648 and 0.605 respectively, P < 0.001) and relatively weaker for hands (kappa 0.584, P < 0.001). CONCLUSION: The number of telangiectasia might be considered a complementary biomarker to the presence of vascular complications of SSc including PAH, DU and calcinosis. The anatomical regions and level of instruction provided for patient-reported count of telangiectasia need further optimization to be considered reliable and feasible. In addition, future work should consider correlations with nailfold capillaroscopic patterns.
引用
- Wells M, Smith T, Domsic RT, et al. The clinical utility of telangiectasia quantification as markers of vascular disease progression in systemic sclerosis. Rheumatology (Oxford). 2026. PMID: 42172612. doi:10.1093/rheumatology/keag267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。